Literature DB >> 12412784

Primary hyperparathyroidism: lessons from bone histomorphometry.

Erik Fink Eriksen1.   

Abstract

The chronic excessive hypersecretion of parathyroid hormone (PTH) in primary hyperparathyroidism (PHPT) has significant impact on bone remodeling. Bone turnover increases by about 50%, leading to increased resorption at the endosteal envelope, increased cortical porosity, and thinning of cortical bone. In cancellous bone a different response is seen. Despite stimulation of bone resorption and formation at the tissue level, osteoclastic resorption and osteoblastic bone formation at individual bone multicellular units (BMUs) are reduced. This causes reduced erosion depth, reduced bone formation rate, and decreased thickness of bone structural units (BSUs), and bone balance at individual BMUs is preserved and may even improve. Thus, PHPT causes cortical bone loss. At the same time, however, cancellous bone structure remains unchanged or even improved, which may offset cortical bone loss. This probably explains the preservation of bone mass demonstrated in long-term follow-up studies of patients with mild PHPT (S-Ca2+ < 2.80 mM). In severe cases of PHPT (S-Ca2+ > 3.00 mM), the negative effects on cortical bone may override the positive impact on cancellous bone, and lead to bone loss and increased risk of fracture.

Entities:  

Mesh:

Year:  2002        PMID: 12412784

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  14 in total

Review 1.  Parathyroid hormone as an anabolic skeletal therapy.

Authors:  Mishaela R Rubin; John P Bilezikian
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  What is the utility of distal forearm DXA in primary hyperparathyroidism?

Authors:  Kelly Wood; Subarna Dhital; Herbert Chen; Rebecca S Sippel
Journal:  Oncologist       Date:  2012-01-18

Review 3.  Asymptomatic primary hyperparathyroidism.

Authors:  Shonni J Silverberg; Marcella D Walker; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

4.  Bone quality determined by Fourier transform infrared imaging analysis in mild primary hyperparathyroidism.

Authors:  Ruth Zoehrer; David W Dempster; John P Bilezikian; Hua Zhou; Shonni J Silverberg; Elizabeth Shane; Paul Roschger; Eleftherios P Paschalis; Klaus Klaushofer
Journal:  J Clin Endocrinol Metab       Date:  2008-07-01       Impact factor: 5.958

5.  Trabecular bone microarchitecture in mild primary hyperparathyroidism.

Authors:  L Dalle Carbonare; P Ballanti; F Bertoldo; M T Valenti; B Giovanazzi; S Giannini; G Realdi; V Lo Cascio
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

Review 6.  Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.

Authors:  Shonni J Silverberg; E Michael Lewiecki; Leif Mosekilde; Munro Peacock; Mishaela R Rubin
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

Review 7.  Treatment of osteopenia.

Authors:  Erik Fink Eriksen
Journal:  Rev Endocr Metab Disord       Date:  2012-09       Impact factor: 6.514

8.  Effect of parathyroid hormone on hypogonadism induced bone loss of proximal femur of orchiectomized rat.

Authors:  M Tezval; G Serferaz; T Rack; L Kolios; S Sehmisch; U Schmelz; H Tezval; K M Stuermer; E K Stuermer
Journal:  World J Urol       Date:  2011-02-05       Impact factor: 4.226

9.  Mineral composition is altered by osteoblast expression of an engineered G(s)-coupled receptor.

Authors:  G J Kazakia; D Speer; S Shanbhag; S Majumdar; B R Conklin; R A Nissenson; E C Hsiao
Journal:  Calcif Tissue Int       Date:  2011-04-28       Impact factor: 4.333

10.  Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur.

Authors:  M Tezval; E K Stuermer; S Sehmisch; T Rack; A Stary; M Stebener; F Konietschke; K M Stuermer
Journal:  Osteoporos Int       Date:  2009-05-13       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.